Unique Technology Development Monitors Surgical Stress

Q: How has MDoloris’ technological innovation to monitor surgical stress improved medical procedures?

A: The company wanted to contribute to the process of anesthetics and ANI (Analgesia Nociception Index) is the result of such drive. This exclusive technology is the result of 27 years of research. From the beginning, we realized the potential of this development because of how it was able to measure objectively the status of analgesia in a patient. The solution allows anesthesiologist to control a patient’s response to surgical stress and we see its benefits from the beginning of the surgical process to the patient’s recovery. Reduced surgical stress results in shorter hospital stays, less pain and reduced use of analgesics during recovery.

Q: MDoloris also developed NIPE to evaluate and monitor newborns. Why was this development important for the company?

A: Our technologies measure the autonomic nervous system, which helps maintain allostasis within the body, ensuring balance. When people lose that balance, they start to manifests ailments or develop diseases. Newborns experience these same processes much more critically, especially if they are undergoing intensive therapy. During their first 1,000 days of life, newborns are completing the maturation of their autonomic nervous system. If this period is disturbed by repeated periods of stress, which can occur during neonatal intensive care there can be long-term repercussions. This has driven intensivists to develop special care to ensure the comfort of newborns and reduce stress periods. MDoloris wanted to create an objective tool to obtain an exact measurement of the newborn patient’s allostasis during this period of their life. This allows the measurement of comfort levels for an alert patient and measures suffering levels of unconscious patients or patients who are unable to speak, whether it is due to their health status or the procedures they are undergoing. This is a solution for doctors to understand the patient’s body response without the need for verbal feedback from the patient.

Q: How has MDoloris expanded the reach of its technology developments in Mexico?

A: MDoloris reaches doctors through medical associations and groups. It has been a very educational process but overall, Mexico has many doctors who are open to innovation and state-of-the-art developments that help them to perform better as professionals and that benefit their patients.

We have approached institutions to introduce our products to the market. We created commercial and economic strategies to target medical facilities. We are offering this technology for free to hospitals through Conduit Life, our distributor in Mexico, only charging for sensor use. MDoloris is a very serious and ambitious company and we are mostly working with private hospitals at this stage. The work we do with the public sector is through research protocols. We have a worldwide partnership with Masimo which helps to consolidate our presence with hospitals who use their monitors. 

Q: How has MDoloris used its experience in Mexico to grow in other regions?

A: Our experience working in Mexico has helped to open doors in different countries in Latin America. Doctors in Mexico share their knowledge with their colleagues and, therefore, word of mouth spreads through the medical community, making it easier for us to introduce our solutions.

Q: What does MDoloris have in its R&D pipeline?

A: Our R&D team is developing two projects. The first seeks to improve titration of analgesics with a close loop system in the surgical environment and the second focuses on pain therapy for chronic diseases, palliative care or home-care.

Q: How is MDoloris participating in the efforts to fight COVID-19?

A: Our solutions are being tested on patients with severe COVID-19 symptoms, including inflammation. The results of a clinical trial already performed in Europe, showed that through our nervous system measurements, doctors can determine the capacity that patients have to fight for their lives and recover. Our equipment delivers high-precision results to predict morbidity in patients and it has been surprisingly effective for doctors as a non-invasive method to continuously measure the nervous system. The second clinical outcome on COVID-19 ventilated patients was that, when able to personalize the analgesics in ICU, we avoid the side effect of overdosage, which includes respiratory failures and inflammation responses which both are critical to prevent. Additionally, the Spanish Intensivist Society (SEMYCIUC) has recommended the use of ANI to titrate analgesics in this kind of patients.

We are about to begin a protocol to measure the nervous system in recently checked-in patients before they present severe symptoms. The goal is to use our technology to avoid the development of severe symptoms. We are also about to begin another study in ICU on patients with COVID-19 and patients with sepsis, which have a very similar symptom chart to COVID-19.

Q: What are the company’s near-term goals?

A: MDoloris wants to become a standard in patient monitoring the anesthesia environment. We are looking forward to concluding our protocols for COVID-19 ICU patients because it is a way for us to consolidate our presence in operating rooms and in the areas of intense therapy surgeries and neonatal critical care units in Mexico, in addition to the 200 international peer reviewed papers that confirm the accuracy of our technology. Finally, in the short term, we are about to disclose another worldwide OEM partnership. 

MDoloris Medical Systems is the first worldwide company to provide clinicians continuous, non-invasive surgical stress-monitoring medical devices to help improve patient outcomes.